These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 30875504

  • 1. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L.
    Eur J Med Chem; 2019 May 01; 169():121-143. PubMed ID: 30875504
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X, Yang D, Fan Z, Zhang N, Zhao B, Huang C, Wang F, Ma R, Meng M, Deng Y.
    Eur J Med Chem; 2019 Sep 15; 178():767-781. PubMed ID: 31234030
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ, Song PR, Dou D, Diao YY, Tong LJ, Zhang T, Xie H, Li HL, Ding J.
    Acta Pharmacol Sin; 2020 Mar 15; 41(3):415-422. PubMed ID: 31316181
    [Abstract] [Full Text] [Related]

  • 9. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
    Kawahata W, Asami T, Kiyoi T, Irie T, Taniguchi H, Asamitsu Y, Inoue T, Miyake T, Sawa M.
    J Med Chem; 2018 Oct 11; 61(19):8917-8933. PubMed ID: 30216722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.
    He L, Zhang J, Ling Z, Zeng X, Yao H, Tang M, Huang H, Xie X, Qin T, Feng X, Chen Z, Deng F, Yue X.
    Bioorg Chem; 2024 Aug 11; 149():107499. PubMed ID: 38815476
    [Abstract] [Full Text] [Related]

  • 13. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
    Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J, Deng X.
    Br J Pharmacol; 2019 Dec 11; 176(23):4491-4509. PubMed ID: 31364164
    [Abstract] [Full Text] [Related]

  • 14. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
    Chough C, Joung M, Lee S, Lee J, Kim JH, Kim BM.
    Bioorg Med Chem; 2018 May 01; 26(8):1495-1510. PubMed ID: 29452839
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.
    Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1867-1873. PubMed ID: 28279528
    [Abstract] [Full Text] [Related]

  • 17. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y, Lu X, Xiao M, Li Z, Zou Y, Ren S, Cheng Y, Luo G, Xiang H.
    Eur J Med Chem; 2020 Aug 01; 199():112339. PubMed ID: 32402933
    [Abstract] [Full Text] [Related]

  • 18. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.
    Liu YT, Ding HH, Lin ZM, Wang Q, Chen L, Liu SS, Yang XQ, Zhu FH, Huang YT, Cao SQ, Yang FM, Song ZL, Ding J, Geng MY, Xie H, Zhang A, He SJ, Zuo JP.
    Acta Pharmacol Sin; 2021 Oct 01; 42(10):1653-1664. PubMed ID: 33441995
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y, Shu Y, Lin J, Chen Z, Xie Q, Bao Y, Lu L, Sun N, Wang Y.
    Eur J Med Chem; 2021 Dec 05; 225():113820. PubMed ID: 34509879
    [Abstract] [Full Text] [Related]

  • 20. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F, Liu Y, Liu M, Zhang D, Wang P, Dong J, Tang W, Zhao G.
    Bioorg Chem; 2019 Aug 05; 89():102943. PubMed ID: 31031018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.